- respiratory failure at screening - history of heart failure - history of copd or bronchial asthma - active tb or history of tb of the following types - uncontrolled arrhythmia within 3 months prior to randomization - heart disease of the following types - moderate to severe renal insufficiency - abnormal white cell and platelet counts - history of transplantation of vital organs (e.g., heart, lung, liver, and/or kidney); - malignant tumor - uncontrolled systemic or local autoimmune or inflammatory disease besides sars-cov-2 - unhealed wounds, active gastric ulcer, had surgery - received other investigational therapeutic products - used interferon therapies - history of hiv infection, hepatitis b, and/or hepatitis c - known serious allergic reaction or hypersensitivity to components of f-652 - pregnant or breastfeeding - history of drug abuse or use of narcotics - treated with immunomodulators or immunosuppressants - other conditions resulting in increased risk

- respiratory failure at screening - history of heart failure - history of copd or bronchial asthma - active tb or history of tb of the following types - uncontrolled arrhythmia within 3 months prior to randomization - heart disease of the following types - moderate to severe renal insufficiency - abnormal white cell and platelet counts - history of transplantation of vital organs (e.g., heart, lung, liver, and/or kidney); - malignant tumor - uncontrolled systemic or local autoimmune or inflammatory disease besides sars-cov-2 - unhealed wounds, active gastric ulcer, had surgery - received other investigational therapeutic products - used interferon therapies - history of hiv infection, hepatitis b, and/or hepatitis c - known serious allergic reaction or hypersensitivity to components of f-652 - pregnant or breastfeeding - history of drug abuse or use of narcotics - treated with immunomodulators or immunosuppressants - other conditions resulting in increased risk